Castle Biosciences to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Nov 8, 2018--Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced that Derek Maetzold, President and CEO, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 th, 2018 at 3:00 p.m. in New York City.
About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx ® -Melanoma, DecisionDx ® -CM Seq; www.SkinMelanoma.com ) and uveal melanoma (DecisionDx ® -UM, DecisionDx ® -PRAME and DecisionDx ® -UM Seq; www.MyUvealMelanoma.com ), with development programs in other underserved cancers, the most advanced of which is focused on patients with cutaneous squamous cell carcinoma. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. More information can be found at www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181108005245/en/
CONTACT: Castle Biosciences
Frank Stokes, 866-788-9007
Chief Financial Officer
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK TEXAS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Castle Biosciences, Inc.
Copyright Business Wire 2018.
PUB: 11/08/2018 07:00 AM/DISC: 11/08/2018 07:00 AM